Multimodal imaging in a case of deferoxamine-induced maculopathy.
OBJECTIVE
To report a case of deferoxamine-induced maculopathy and present the use of multimodal retinal imaging to study this disease entity.


METHODS
This is an observational case report of one patient. Multimodal imaging with fundus autofluorescence, infrared imaging, and spectral domain optical coherence tomography was used to investigate the macular changes induced by deferoxamine toxicity.


RESULTS
A 53-year-old man with history of β-thalassemia presented with decreased vision in both eyes 1 month after initiating deferoxamine therapy. Infrared imaging showed areas of increased stippled infrared intensity through the macula. Fundus autofluorescence revealed diffuse areas of stippled hyperautofluorescence and hypoautofluorescence. Spectral domain optical coherence tomography changes included disruption of the ellipsoid zone, attenuation of the photoreceptors, and deposits within the retinal pigment epithelium.


CONCLUSIONS
A case of deferoxamine-induced maculopathy was described and the use of multimodal retinal imaging to study this disease entity was presented.
*Department of Ophthalmology, University of Southern California, Los Angeles, California; †Edward S. Harkness Eye Institute, College of Physicians and Surgeons, Columbia University, New York, New York; ‡Deparment of Pathology and Cell Biology, College of Physicians and Surgeons, Columbia University, New York, New York; §Department of Ophthalmology, Weill Cornell Medical College, New York, New York; and ¶Barbara and Donald Jonas Laboratory of Stem Cell and Regenerative Medicine, College of Physicians and Surgeons, Columbia University, New York, New York.
Rony
R
Gelman
Szilard
S
Kiss
Stephen H
SH
Tsang
D003676:Deferoxamine / Q000009:adverse effects*; D006801:Humans; D007502:Iron Chelating Agents / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D012164:Retinal Diseases / Q000139:chemically induced*; D017262:Siderophores / Q000009:adverse effects*; D014786:Vision Disorders / Q000139:chemically induced*; D017086:beta-Thalassemia / Q000188:drug therapy
D007502:Iron Chelating Agents; D017262:Siderophores; D003676:Deferoxamine